Naltrexone (oral and IM depot)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-NALTREXONE-PO |
|---|---|
| Type | Drug |
| Aliases | DepadeNaltrexoneReViaVivitrol (IM depot)Налтрексон (пероральний і депо-IM) |
| Status | reviewed 2026-05-18 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-NCCN-BCELL-2025 |
Drug Facts
| Class | Opioid receptor antagonist (μ, κ, δ) |
|---|---|
| Mechanism | Competitive antagonist at opioid receptors. In alcohol use disorder (AUD), blocks endogenous opioid-mediated reward signaling triggered by alcohol ingestion → reduces craving and heavy-drinking days. First-line FDA-approved AUD pharmacotherapy (alongside acamprosate and disulfiram). Also FDA-approved for opioid use disorder (block opioid effect — requires opioid-free interval first). |
| Typical dosing | AUD: PO: 50 mg once daily (some protocols use 25 mg × 1-2 days to assess tolerance, then escalate); can extend to 100 mg if needed. IM depot (Vivitrol): 380 mg deep IM gluteal every 4 weeks; preferred if adherence is a concern. Verify opioid-free for ≥7-10 days before first IM dose (precipitated withdrawal otherwise). |
| Ukraine registered | True |
| NSZU reimbursed | False |
| Ukraine last verified | 2026-05-18 |
Warnings
- Hepatotoxicity at supratherapeutic doses (originally noted at 300 mg/d; uncommon at 50 mg/d but LFT monitoring recommended)
Notes
STUB — v0.2 prevention-workstream authoring; pending two-Clinical-Co-Lead signoff per CHARTER §6.1 dev-mode. First-line AUD pharmacotherapy (NIAAA + APA). Both oral and IM depot superior to placebo at reducing heavy-drinking days; IM depot preferred when adherence challenging. Critical: must be opioid-free ≥7-10 days before initiation. Alcohol cessation/reduction is a cancer-prevention intervention (HCC, CRC, esophageal SCC, breast). Source cited (SRC-NCCN-BCELL-2025) is closest in-KB until NIAAA/APA AUD sources land in source-stub workstream.
Used By
Regimens
REG-NALTREXONE-AUD- Naltrexone for alcohol use disorder (PO daily or IM monthly)